Hexamethylene Amiloride Induces Cell Death in Multiple Myeloma
Author Information
Author(s): Yang Nianhui, Dong Zexuan, Xiao Weihao, Deng Suqi, Li Yizhen, Hua Lei, Li Yue, Wu Yingying, Huang Kexiu, Zhou Wei, Wang Hua, Li Yonghua, Du Juan, Zeng Hui
Primary Institution: The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Hypothesis
Can Hexamethylene amiloride inhibit multiple myeloma growth and induce apoptosis?
Conclusion
Hexamethylene amiloride effectively inhibits multiple myeloma growth and induces apoptosis in both cell lines and primary patient cells.
Supporting Evidence
- Hexamethylene amiloride significantly decreased the viability of multiple myeloma cell lines in a dose-dependent manner.
- HA treatment induced apoptosis in 31.2% of RPMI-8226 cells and 45% of U266 cells at 10µM.
- HA was effective in overcoming carfilzomib resistance in multiple myeloma cells.
- HA treatment resulted in increased lysosome biogenesis and altered lysosomal membrane permeability.
- Elevated NHE1 expression was associated with poor prognosis in multiple myeloma patients.
Takeaway
A drug called Hexamethylene amiloride can help kill cancer cells in a type of blood cancer called multiple myeloma.
Methodology
The study involved treating multiple myeloma cell lines and primary cells from patients with Hexamethylene amiloride and assessing cell viability and apoptosis.
Limitations
The study primarily focused on in vitro and in vivo models, and further clinical trials are needed to confirm findings in humans.
Participant Demographics
Patients with multiple myeloma were included, with samples collected from ten individuals.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website